APUS Company Profile and Key Details

Short-term trend indicators are bullishly aligned (SMA20 -8.14%, SMA50 -18.09%, SMA200 -27.98%). The stock’s 14-day RSI is 45.21 (neutral), while the ATR of 0.24 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -66.26% below its high and over 43.01% above its low.

Apimeds Pharmaceuticals US, Inc last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.47. This means the shares are trading below this model’s fair value.

The stock is currently mid-range between its 52-week high and low $1.61 and $40.31. With a market capitalization of about $2.36 million, Apimeds Pharmaceuticals US, Inc is classified as a micro-cap and shows lower-than-market volatility (beta ~-1.37). Key stats such as the average daily volume over the past year has been around 22.52 thousand shares, in line with its 52-week average. Headquartered in Hopewell, NJ, Apimeds Pharmaceuticals US, Inc operates in the Healthcare sector and the Drug Manufacturers - Specialty & Generic industry. Led by CEO Vinod Menon, the company employs approximately 2 people and listed since May 09, 2025. Apimeds Pharmaceuticals US, Inc. operates as a clinical stage biopharmaceutical company in the United States.

Apimeds Pharmaceuticals US, Inc trades at a P/E ratio of -0.46, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 0.29 suggesting the stock is closer to book value. The P/FCF stands at -0.45, also below market averages.

Apimeds Pharmaceuticals US, Inc (AMEX:APUS) shares are flat 2.44% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Apimeds Pharmaceuticals US, Inc trading at a premium to the broader market with a P/E of -0.46. Our AI forecast model points to short-term strength (9.57% over two weeks), a medium-term fall (-77.13% over three months), and a longer-term gain (292.55% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Apimeds Pharmaceuticals US, Inc stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 9.57%, with price expected at $2.06 by April 20, 2026, within a range of $1.87 to $2.26 3-Month Outlook: Projected fall of -77.13%, reaching $0.43 by July 03, 2026, with a range of $0.34 to $0.50. 1-Year Outlook: Projected gain of 292.55%, with price at $7.38 by April 06, 2027, within a range of $7.15 to $7.57.